Search

Amgen Inc

Gesloten

SectorGezondheidszorg

409.97 4.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

379.52

Max

394.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-3.6B

-1.8B

Verkoop

1.4B

10B

K/W

Sectorgemiddelde

23.681

56.432

EPS

6.29

Dividendrendement

2.6

Winstmarge

-18.092

Werknemers

31,500

EBITDA

-416M

3.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+3.39% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

2.60%

2.27%

Volgende Winsten

3 nov 2026

Volgende dividenddatum

11 dec 2026

Volgende Ex Dividend datum

20 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.8B

206B

Vorige openingsprijs

405.7

Vorige sluitingsprijs

409.97

Nieuwssentiment

By Acuity

53%

47%

247 / 339 Rangschikking in Healthcare

Amgen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17 sep 2026, 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16 sep 2026, 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15 sep 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14 sep 2026, 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11 sep 2026, 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10 sep 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8 sep 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 sep 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 sep 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 sep 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1 sep 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31 aug 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28 aug 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27 aug 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26 aug 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25 aug 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24 aug 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21 aug 2026, 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20 aug 2026, 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19 aug 2026, 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18 aug 2026, 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17 aug 2026, 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14 aug 2026, 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13 aug 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12 aug 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11 aug 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7 aug 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6 aug 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5 aug 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

Peer Vergelijking

Prijswijziging

Amgen Inc Prognose

Koersdoel

By TipRanks

3.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 398.727 USD  3.39%

Hoogste 460 USD

Laagste 230 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Amgen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

24 ratings

9

Buy

13

Hold

2

Sell

Sentiment

By Acuity

247 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.